A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cystic Fibrosis population
This study, called a 'low-intervention prospective-retrospective study', is looking at how a key cystic fibrosis medicine, Kaftrio (elexacaftor/tezacaftor/ivacaftor), works in the body. Specifically, researchers want to measure the levels of these medicines in the blood of people with cystic fibrosis. They will also look at how these levels might link to any side effects experienced and how well the medicine is helping to improve lung function and other CF symptoms. This type of study helps doctors understand more about how existing medicines work in real-world settings, ensuring patients get the most effective and safest treatment possible. It can also help to identify if different people need different doses.
At a glance
What is this study about?
This study is about a medicine called Kaftrio (also known by its and its ingredients elexacaftor, tezacaftor, and ivacaftor), which is used to treat cystic fibrosis. When you take a medicine, your body processes it – it absorbs it, uses it, and then gets rid of it. Doctors call this 'pharmacokinetics'. In this study, the main goal is to measure how much of the Kaftrio medicine is in your blood once you've been taking it regularly and the levels have settled, which is called 'steady state'. This tells us how well the medicine is being absorbed and processed by your body.
Understanding these blood levels is really important. It helps doctors know if patients are getting the right amount of medicine. Too little might mean it's not working effectively, and too much could lead to more side effects. By carefully looking at the levels in the blood, the study hopes to learn if there's a link between how much medicine is in your system, any side effects you might experience, and how well your cystic fibrosis is improving, for example, your lung function.
This is a 'Phase IV' study, which means it’s looking at a medicine that is already approved and being used by patients. It’s a chance to gather more information about how Kaftrio works in a larger number of people in everyday life, not just in strict trial conditions. This helps healthcare professionals make the best decisions for people with cystic fibrosis.
Key takeaways
- The study looks at how the CF medicine Kaftrio works in your body.
- It measures medicine levels in your blood to understand its effects.
- It aims to link medicine levels to side effects and treatment benefits.
- This is for adults (18+) with Cystic Fibrosis who are already on Kaftrio.
- Participation mainly involves occasional blood tests and reviewing medical records.
- It helps improve future care for people with Cystic Fibrosis.
Who may be eligible?
This study is looking for adults who are at least 18 years old. Both men and women can take part in this study.
To be considered, you will likely need to have a confirmed diagnosis of Cystic Fibrosis and already be taking Kaftrio as part of your regular treatment. The study is focused on people who are already using this medicine.
More specific details about your medical history, current health, and other medicines you might be taking would be discussed by the study team to confirm if the study is right for you.
- Are you 18 years old or older?
- Do you have a diagnosis of Cystic Fibrosis?
- Are you currently taking Kaftrio (elexacaftor/tezacaftor/ivacaftor) as prescribed?
- Are you able to provide blood samples for the study?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, the main thing you would need to do is provide blood samples. These blood samples will be used to measure the levels of the Kaftrio medicine in your system. This would happen when you’re already taking the medicine regularly, after it has had time to build up in your body to a stable level.
The study will also involve looking at your existing medical records for information about your health, such as any changes in your lung function (how well your lungs work) and any side effects you may have experienced while on Kaftrio. You would continue to take your Kaftrio as prescribed by your doctor. The study will not involve changing your current treatment plan, but rather monitoring how it's working for you. The total duration of your participation would depend on the study's specific schedule for blood tests and data collection, but it aims to collect information over a period while you are already on the medication.
Potential risks and benefits
Locations (1)
- —Italy
Common questions
What is Cystic Fibrosis?
Cystic Fibrosis (CF) is a genetic condition that causes thick, sticky mucus to build up in the lungs, digestive system, and other organs, leading to breathing and digestion problems.
What is Kaftrio?
Kaftrio is a medicine for cystic fibrosis that helps a specific protein in the body (CFTR) work better, which can make the mucus thinner and improve symptoms.
Why is this study important?
This study helps doctors understand how Kaftrio works inside the body, how much is needed, and how it relates to side effects and how well patients improve. This helps ensure better care for people with CF.
Will I have to stop taking my other medicines?
No, this study is about monitoring Kaftrio while you are already taking it as prescribed. It is unlikely to involve changes to your existing medication plan, but this would be fully discussed.
What is 'steady state'?
Steady state is when the amount of medicine going into your body is balanced with the amount leaving it, so the levels in your blood stay relatively stable over time after regular dosing.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.